229 related articles for article (PubMed ID: 25274211)
21. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
22. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
23. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.
Itamura H; Shindo T; Tawara I; Kubota Y; Kariya R; Okada S; Komanduri KV; Kimura S
JCI Insight; 2016 Jul; 1(10):e86331. PubMed ID: 27699218
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
[TBL] [Abstract][Full Text] [Related]
25. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
[TBL] [Abstract][Full Text] [Related]
26. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
27. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
28. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
29. A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effect.
Thompson LF; Tsukamoto H; Chernogorova P; Zeiser R
Oncoimmunology; 2013 Jan; 2(1):e22107. PubMed ID: 23482243
[TBL] [Abstract][Full Text] [Related]
30. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
31. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
32. T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.
Fu J; Wu Y; Nguyen H; Heinrichs J; Schutt S; Liu Y; Liu C; Jin J; Anasetti C; Yu XZ
J Immunol; 2016 Apr; 196(7):3168-79. PubMed ID: 26903480
[TBL] [Abstract][Full Text] [Related]
33. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
[TBL] [Abstract][Full Text] [Related]
35. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
36. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
[TBL] [Abstract][Full Text] [Related]
37. Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation.
Chernogorova P; Zeiser R
J Biomed Biotechnol; 2012; 2012():208204. PubMed ID: 23125523
[TBL] [Abstract][Full Text] [Related]
38. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
39. Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation.
Berrie JL; Kmieciak M; Sabo RT; Roberts CH; Idowu MO; Mallory K; Chung HM; McCarty JM; Borrelli CA; Detwiler MM; Kazim AL; Toor AA; Manjili MH
Transplantation; 2012 May; 93(9):949-57. PubMed ID: 22377792
[TBL] [Abstract][Full Text] [Related]
40. Purinergic signalling in graft-versus-host disease.
Sluyter R; Cuthbertson P; Elhage A; Sligar C; Watson D
Curr Opin Pharmacol; 2023 Feb; 68():102346. PubMed ID: 36634595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
